ABSTRACT
The replacement of petrochemicals with biobased chemicals requires efficient bioprocesses, biocatalysis, and product recovery. Biocatalysis (e.g., enzyme conversion and fermentation) offers an attractive alternative to chemical processing because biocatalysis utilize renewable feedstocks under benign reaction conditions. One class of chemical products that could be produced in large volumes by biocatalysis is organic acids. However, biocatalytic reactions to produce organic acids typically result in only dilute concentrations of the product because of product inhibition and acidification that drives the reaction pH outside of the optimal range for the biocatalyst. Buffering or neutralization results in formation of the acid salt rather than the acid, which requires further processing to recover the free acid product. To address these barriers to biocatalytic organic acid production, we developed the "separative bioreactor" based on resin wafer electrodeionization, which is an electro-deionization platform that uses resin wafers fabricated from ion exchange resins. The separative bioreactor simultaneously separates the organic acid from the biocatalyst as it is produced, thus it avoids product inhibition enhancing reaction rates. In addition, the separative bioreactor recovers the product in its acid form to avoid neutralization. The instantaneous separation of acid upon formation in the separative bioreactor is one of the first truly one-step systems for producing organic acids. The separative bioreactor was demonstrated with two systems. In the first demonstration, the enzyme glucose fructose oxidoreductase (GFOR) was immobilized in the reactor and later regenerated in situ. GFOR produced gluconic acid (in its acid form) continuously for 7 days with production rates up to 1000 mg/L/hr at >99% product recovery and GFOR reactivity >30mg gluconic acid/mg GFOR/hour. In the second demonstration, the E. coli strain CSM1 produced lactic acid for up to 24 hours with a productivity of >200 mg/L/hr and almost 100% product recovery.
ABSTRACT
BACKGROUND: Human, but not mouse, islet amyloid polypeptide (IAPP) is amyloidogenic. Transgenic mice overexpressing human IAPP in the beta cells of the islets of Langerhans should be useful in identifying factors important for the deposition of IAPP as insoluble amyloid fibrils. MATERIALS AND METHODS: Transgenic mice expressing human IAPP were examined using several experimental models for the production of persistent hyperglycemia, as well as for the overstimulation and/or inhibition of beta cell secretion. Obesity was induced by aurothioglucose. Persistent hyperglycemia was produced by long-term administration of glucocorticosteroids or by partial pancreatectomy. Inhibition of normal beta cell exocytosis by diazoxide administration, with or without concurrent dexamethasone injections, was carried out to increase crinophagy of secretory granules. The human IAPP gene was also introduced into the ab and ob mouse models for diabetes. Finally, isolated islets cultivated in vitro at high glucose concentration were also examined. RESULTS: No amyloid deposits were found in the pancreata of any of the animals, either by light microscopy after Congo red staining or by electron microscopy after immunogold labeling with antibodies specific for human IAPP. Aurothioglucose treatment resulted in increased numbers of granules in the beta cell and the appearance of large lysosomal bodies without amyloid. However, islets from db and ob mice expressing human IAPP cultivated in vitro in the presence of glucocorticosteroid and/or growth hormone, were found to contain extracellular amyloid deposits reacting with antibodies to human IAPP. CONCLUSIONS: Oversecretion of human IAPP or increased crinophagy are not sufficient for amyloid formation. This indicates that other factors must influence amyloid deposition; one such factor may be the local clearance of IAPP.
